Cysticercosis laboratory findings

Jump to navigation Jump to search

Cysticercosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cysticercosis from Other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Case Studies

Case #1

Cysticercosis laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cysticercosis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cysticercosis laboratory findings

CDC on Cysticercosis laboratory findings

Cysticercosis laboratory findings in the news

Blogs on Cysticercosis laboratory findings

Directions to Hospitals Treating Cysticercosis

Risk calculators and risk factors for Cysticercosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Diagnostic criteria

A set of diagnostic criteria were proposed by Del Brutto et al based on the laboratory and imaging tests. The criteria were modified in 2001 to be: (22)

Categories Details
Absolute
  • Cystic lesions with the scolex in it on CT scan or MRI
  • Histologic confirmation of the parasite on a biopsy from a lesion in the brain or spinal cord
  • Visualization of subretinal parasites directly using funduscopic examination
Major
  • Positivity of serum anticysticercal antibodies using enzyme-linked immunoelectrotransfer blot assay (EITB)
  • Highly suggestive lesions of neurocysticercosis on neuroimaging
  • Resolution of small single enhancing lesions spontaneously
  • Resolution of intracranial cystic lesions after trreatment with albendazole or praziquantel
Minor
  • Lesions that are compatible with neurocysticercosis on neuroimaging (CT or MRI)
  • Clinical presentation that is suggestive of neurocysticercosis.
  • Positive findings from cerebrospinal fluid enzyme-linked immunosorbent assay (ELISA) for detection of anticysticercal antibodies or cysticercal antigens
  • Diagnosing cysticercosis remotely (outside the central nervous system)
Epidemiologic
  • Evidence of T.solium infection in a household contact
  • Individuals who are staying in or coming from an area of cysticercosis endemicity
  • Household contact with an individual infected with T solium
  • History of travelling frequently to a disease endemic areas
Certainity of diagnosis after applying the criteria
Certainity of diagnosis Details
Definitive
  • Fulfilling 1 absolute criterion
  • Fulfilling 2 major criteria in addition to 1 minor criterion and 1 epidemiologic criterion
Probable
  • Fulfilling 1 major criterion in addition to 2 minor criteria
  • Fulfilling 1 major criterion in addition to 1 minor criterion and 1 epidemiologic criterion
  • Fulfilling 3 minor criteria in addition to 1 epidemiologic criterion

Laboratory Findings

The definitive diagnosis consists of demonstrating the cysticercus in the tissue involved. Demonstration of Taenia solium eggs and proglottids in the feces diagnoses taeniasis and not cysticercosis. While suggestive, it does not necessarily prove that cysticercosis is present. Persons who are found to have eggs or proglottids in their feces should be evaluated serologically since autoinfection, resulting in cysticercosis, can occur.

Cysticercosis: Antibody Detection

  • CDC's immunoblot is based on detection of antibody to one or more of 7 lentil-lectin purified structural glycoprotein antigens from the larval cysts of T. solium in an immunoblot format.
  • It is 100% specific and has a sensitivity superior to that of any other test yet evaluated. Serum specimens from 97% of parasitologically confirmed cases of cysticercosis have detectable antibodies. No serum samples from patients with other microbial infections react with any of the T. solium-specific antigens.
  • The most important factors identified as determining positive immunoblot reactions are the numbers and stage of development of cysticerci. Cumulative clinical experience has confirmed that in patients with multiple (more than two) lesions, the test has more than 95% sensitivity. Seropositivity in biopsy-confirmed patients with single, enhancing parenchymal cysts was <50%; in clinically defined patients with a single cyst but who were not biopsied, sensitivity was 70%. Seropositivity in serum and CSF of patients with multiple but only calcified cysts was 82 and 77%, respectively.
  • In all patients, regardless of their clinical presentation, the immunoblot assay is slightly more sensitive in serum than in CSF specimens: consequently, there is no need to obtain CSF solely for use in the immunoblot assay.
  • CDC's immunoblot is both more specific and more sensitive than enzyme immunoassay (EIA) systems with which it has been compared. Lack of specificity has been a major problem in most EIAs because of cross-reacting components in crude antigens derived from cysticerci; these components react with antibodies specific for other helminthic infections, especially echinococcosis and filariasis. Most partially purified fractions evaluated in an EIA appear to have lower sensitivity than crude antigens and do not necessarily achieve higher specificity. Assays employing crude antigens for the detection of antibody are not reliable for the identification of this disease; all positives and any negative strongly suspected of cysticercosis should be confirmed by immunoblot. Currently available antibody detection tests for cysticercosis do not distinguish between active and inactive infections and thus have not been useful in evaluating the outcomes and prognoses of medically treated patients. Both the CDC immunoblot and an EIA are commercially available in the United States.
  • CDC's immunoblot assay with purified Taenia solium antigens has been acknowledged by the World Health Organization and the Pan American Health Organization as the immunodiagnostic test of choice for confirming a clinical and radiologic presumptive diagnosis of neurocysticercosis.
Cysticercosis immunoblot
  • Typical antibody reactions in CDC's immunoblot for cysticercosis. Individual sera from patients with either cysticercosis or echinococcosis were analyzed using the immunoblot for cysticercosis.
  • Cysticercosis-specific antibodies react with glycoproteins derived from T. solium cysts. The positions of the seven diagnostic glycoproteins are marked and designated according to their relative mobilities in SDS-PAGE. Sera from patients with cysticercosis react with at least one of the cysticercosis-specific proteins, whereas sera from patients with echinococcosis do not react with any of the seven diagnostic proteins.

Stool Examination

Microscopic identification of eggs and proglottids in feces is diagnostic for taeniasis; however, eggs and proglottids are not released into the feces until approximately 2 to 3 months after the adult tapeworm is established in the upper jejunum. Repeated examination and concentration techniques will increase the likelihood of detecting light infections. Examination of 3 stool samples collected on different days is recommended to increase the sensitivity of microscopic methods. Eggs of Taenia spp. cannot be differentiated; a species determination may be possible if mature, gravid proglottids (or, more rarely, examination of the scolex) are present.

External Link

http://www.cdc.gov/parasites/taeniasis/health_professionals/index.html

References


Template:WikiDoc Sources